Bionano - Gang- Clubhouse Forum: Community User: Perstoper21

Und als letztes :) :

Selling and marketing costs decreased 11% to $27.2 million, compared to $30.5 million in the first quarter of 2021 due primarily to lower media and agency fees, which were offset in part by costs related to the Phexxi sample rollout. General and administrative costs were $6.4 million compared to $7.7 million in the first quarter of 2021, primarily reflecting lower headcount, recruiting, and outside services. During the second quarter, the Company implemented cost containment measures across all departments. These included reductions in spend and headcount, elimination of certain consulting roles, and eliminating hires planned for 2021. These measures are expected to result in aggregate savings of $9.5 million on an annualized basis. Total other income, net, was $7.7 million in the second quarter of 2021, and mainly included a $8.9 million change in fair value as a result of mark-to-market adjustments and $1.2 million in interest expense for the convertible notes issued in 2020.

Financial Results For the three months ended June 30, 2021, Phexxi net product sales increased 68% to $1.9 million, compared to $1.1 million in the three months ended March 31, 2021. There were no net product sales in the second quarter of 2020, since Phexxi was launched in the U.S. in September 2020. Total operating expenses decreased 6% to $43.0 million for the second quarter of 2021 compared to $46.0 million in the first quarter of 2021. Cost of goods sold was $0.8 million, compared to $0.5 million in the first quarter of 2021, reflecting higher Phexxi sales. Research and development costs increased 17% to $8.5 million, compared to $7.3 million in the first quarter of 2021, reflecting higher enrollment in the Phase 3 EVOGUARD trial. This trial is funded in part by the proceeds from the Adjuvant convertible notes issued in 2020.

12,763 Phexxi® (lactic acid, citric acid and potassium bitartrate) prescriptions were filled and 14,810 units were dispensed to patients during the second quarter of 2021, an increase of 47% and 65%, respectively, compared to the first quarter of 2021. 52% growth in the prescriber base in the second quarter of 2021 compared to the first quarter of 2021, and over 7,700 healthcare providers have prescribed Phexxi from launch through mid-July. National brand ambassador campaign featuring an Emmy Award-winning celebrity launching in September 2021 to accelerate growth in Phexxi brand awareness and prescriptions. On track to complete enrollment in EVOGUARD by year-end 2021. This pivotal Phase 3 clinical trial is evaluating safety and efficacy of EVO100 for the prevention of chlamydia and gonorrhea in women.

Ich gehe das Risiko gerne ein , nur so komme ich an meine Gewinne :) Börse ist grundsätzlich Risiko . Trotzdem danke für deine Sichtweise :) 👍🤓

Also erwartest du große Umsatzsprünge im nächsten halben Jahr? Soweit ich weiß wollen die in Q3 einen Werbedeal mit einem Star eintüten. Wird auch wieder teuer. Aber vielleicht explodieren dann auch die Sales? Ich finde zu viel Risiko.

2.3$ Letztes offering . RS nicht geplant , macht auch keinen Sinn . Umsatz ist gestiegen . Zahlen waren gut . Ende 2021 abwarten ;)

Know

Wenn dem so wäre , hätte ich nicht investiert :) no your Investment ;)

Aufpassen bei Evofem! Offering und im Anschluss Reverse Split incoming. Sales von 2m stehen 27m cash burn entgegen. So schnell können die nicht den Umsatz steigen, bis die nächste Offering und ein RS kommen.

Leckomio per gerade so die Kurve ;-)

Wieder Absicht … naja so ist die Börse halt ☝🏻

0,75 war da … bisher klappt es ;)

Scheint gehalten zu haben ;-)

Wenn wir jetzt ein Interpolationspolynom bilden,... Dann ⬆️

Es bildet sich ein Sattelpunkt aus